Oculis (NASDAQ:OCS) Upgraded by Wall Street Zen to "Hold" Rating

Key Points

• Oculis (NASDAQ:OCS) has been upgraded from a "sell" rating to a "hold" rating by Wall Street Zen, indicating a more positive outlook for the stock.
• HC Wainwright raised its price target for Oculis from $32.00 to $33.00, while Needham & Company set a $36.00 price objective, reflecting strong analyst confidence with an average rating of "Buy".
• The company reported a quarterly loss of ($0.59) EPS, missing expectations, but generated revenue of $0.25 million, surpassing analyst predictions.

Oculis (NASDAQ:OCS - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Saturday.

OCS has been the subject of a number of other reports. HC Wainwright increased their price target on shares of Oculis from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Friday, August 22nd. Needham & Company LLC began coverage on shares of Oculis in a research report on Wednesday, August 27th. They set a "buy" rating and a $36.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $35.75.

Oculis Stock Performance

NASDAQ:OCS opened at $17.40 on Friday. Oculis has a twelve month low of $11.78 and a twelve month high of $23.08. The company has a current ratio of 4.55, a quick ratio of 4.55 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average of $17.67 and a 200-day moving average of $18.24. The firm has a market cap of $759.68 million, a price-to-earnings ratio of -6.52 and a beta of 0.26.

Oculis (NASDAQ:OCS - Get Free Report) last posted its quarterly earnings data on Thursday, August 21st. The company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.06). Oculis had a negative net margin of 13,958.12% and a negative return on equity of 90.31%. The firm had revenue of $0.25 million for the quarter, compared to analysts' expectations of $0.14 million. Analysts forecast that Oculis will post -2.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Oculis

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OCS. Pivotal bioVenture Partners Investment Advisor LLC grew its holdings in Oculis by 32.4% during the first quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 2,300,774 shares of the company's stock valued at $43,784,000 after purchasing an additional 563,078 shares during the last quarter. SR One Capital Management LP acquired a new position in Oculis during the first quarter valued at approximately $6,137,000. Aberdeen Group plc grew its holdings in Oculis by 24.1% during the first quarter. Aberdeen Group plc now owns 1,253,119 shares of the company's stock valued at $23,847,000 after purchasing an additional 243,695 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in Oculis during the first quarter valued at approximately $2,499,000. Finally, Citadel Advisors LLC acquired a new position in Oculis during the fourth quarter valued at approximately $389,000. Institutional investors and hedge funds own 22.30% of the company's stock.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.